Omar Mamlouk, M.B.B.S.
Department of Emergency Medicine, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2009 | Jordan University of Science and Technology, Irbid, JO, MBBS in Bachelor of Medicine / Bachelor of Surgery |
Postgraduate Training
| 2019-2021 | Clinical Research Curriculum, McGovern Medical School, Houston, Texas |
| 2019-2021 | Advanced Fellowship, Onco-Nephrology, University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2017-2019 | Clinical Fellowship, Nephrology, McGovern Medical School, Houston, Texas |
| 2014-2017 | Clinical Residency, Internal Medicine, Brookdale University Hospital, Brooklyn, New York |
| 2010-2012 | Research Fellowship, Department of Radiology, Harvard Medical School, Boston, Massachusetts |
Licenses & Certifications
| 2022 | Texas Medical Board |
| 2019 | American Board of Nephrology |
| 2017 | American Board of Internal Medicine |
| null | Mississippi State Board of Medical Licensure |
| null | Oklahoma State Board of Medical Licensure |
| null | Alabama Board of Medical Examiners |
| null | Washington State Department of Health |
| null | Georgia Composite Medical Board |
| null | Louisiana State Board of Medical Examiners |
| null | Tennessee Board of Medical Examiners |
| null | Arizona Board of Medical Examiners |
| null | Florida Board of Medicine |
Experience & Service
Administrative Appointments/Responsibilities
Interim Director of Inpatient Hemodialysis, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - 2025
Director of Nephrology Inpatient Service, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present
Other Professional Positions
Website committee co-chair, American Society of Onconephrology, 2022 - 2023
Extramural Institutional Committee Activities
Member, Medical record committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Honors & Awards
| 2023 | Outstanding service and dedicated leadership, American Society of Onco-nephrology |
| 2019 | Outstanding Fellow of the Year Award |
| 2014 | Outstanding Resident of the Year Award |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. CAR T cell therapy for nephrologist. Nephrology APP/Fellow Lecture Series. Houston, Texas, US.
- 2024. Hepato-renal Syndrome. Hospitalist education series. Houston, Texas, US.
- 2024. Protecting diabetic kidneys during cisplatin cancer treatment: Can SGLT-2 inhibitors help?. Poster. Internal Medicine Research Retreat 2024. Houston, Texas, US.
- 2022. Clinical Characteristics and Outcome of Cancer Patients with Reduced Kidney Function and Coronavirus Disease 2019. Conference. Clinical Characteristics and Outcome of Cancer Patients with Reduced Kidney Function and Coronavirus Disease 2019. Houston, TX, US.
Regional Presentations
- 2011. Bystander Effect in Tumor Cells Produced By Iodine125 Labeled Human Lymphocytes. Conference. Bystander Effect in Tumor Cells Produced By Iodine125 Labeled Human Lymphocytes, US.
National Presentations
- 2023. Paraneoplastic Membranoproliferative Glomerulonephritis Associated with Neoplasm Transformation. Poster. American Society of Nephrology Kidney Week. Philadelphia, Pennsylvania, US.
- 2023. CAR T cell in post kidney transplant lymphoproliferative disorder. Invited. American Society of Onconephrology Symposium. Houston, Texas, US.
- 2022. A Pathological Immunological Approach in Evaluating Immune Checkpoint Inhibitor-Induced Nephritis. Poster. American Society of Nephrology- Kidney Week, US.
- 2022. BK Nephropathy in Hematopoietic Stem Cell Transplant Patients: An Upcoming Challenge. Poster. American Society of Nephrology- Kidney Week, US.
- 2022. Renal Pathologies and Patient Outcomes Post Allogeneic Stem Cell Transplantation. Poster. American Society of Nephrology- Kidney Week, US.
- 2022. Infliximab for Treatment of Immune Adverse Events. Poster. American Society of Nephrology- Kidney Week, US.
- 2022. Real-World Incidence of Kidney Manifestations in Patients Treated With New Tyrosine Kinase Inhibitors. Poster. American Society of Nephrology- Kidney Week, US.
- 2022. Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased kidney function. Conference. ASCO. Chicago, IL, US.
- 2020. Kidney Pathology Findings in Patients with AKI Associated with Tyrosine Kinase Inhibitors. Conference. American Society of Nephrology Kidney Week, US.
- 2019. Regorafenib Associated Thrombotic Microangiopathy. Conference. Onconephrology symposium. New York, New York, US.
- 2019. Checkpoint inhibitors: The Double-Edged Sword in Kidney Transplant Patients. Conference. American Society of Nephrology Kidney Week, US.
- 2018. Rituximab success in management of recurrent GVHD of the kidney post allogenic SCT. Conference. Onconephrology symposium. Houston, Texas, US.
- 2018. Double trouble or a separate entity; AKI secondary to ANCA vasculitis with IgG4 nephropathy. Conference. American Society of Nephrology Kidney Week, US.
International Presentations
- 2024. Chronic Kidney Disease Impact on COVID-19 Infection Severity and Outcomes in Cancer Patients. Poster. World Congress of Nephrology. Buenos Aires, AR.
- 2022. PICC lines in patients with chronic kidney disease and cancer: What are we saving the vein for?. Conference. World Congress of Nephrology. Virtual conference.
Selected Publications
Peer-Reviewed Articles
- Cintrón-García, JJ, Patel, M, Andersen, C, Page, VD, Workeneh, BT, Mandayam, S, Al-Dallal, R, Abudayyeh, A, Mamlouk, O. Potential Benefit of Sodium-Glucose Cotransporter 2-Inhibitors in Cisplatin-Associated Nephrotoxicity Among Patients With Cancer Having Diabetes Mellitus. Kidney International Reports 11(6), 2026. e-Pub 2026. PMID: 42179813.
- Shivaraj, K, Mamlouk, O, Tchakarov, A, Patel, K, Abudayyeh, A. Minimal Change Disease Following B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-Cell Therapy. Kidney Medicine 8(5), 2026. e-Pub 2026. PMID: 42004656.
- Youssef, N, Habeeb, M, Chen, H, Alhamal, Z, Mamlouk, O, Lin, Y, Page, VD, Tchakarov, A, Basu, S, Diab, A, Sharma, P, Abudayyeh, A. Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational Evidence. Kidney International Reports 11(1):32-42, 2026. e-Pub 2026. PMID: 41541786.
- Nada Youssef, Masroor Habeeb, Hong Chen, Zainab Alhamal, Mamlouk O, Heather Lin, Valda Page, Amanda Tchakarov, Sreyashi Basu, Adi Diab, Padmanee Sharma, Ala Abudayyeh. Infliximab for Grade III/IV ICI Nephritis Clinical and Translational Evidence. KI reports, 2025.
- Kelly A, Sharma S, Mamlouk O, Hassanein M, Chowdhury R, Gupta S, Truong H, Bonilla M, Kalra K, Wanchoo R, Pariswala T, Turcotte AE, Zaveri I, Dernell C, Ibrahim M, Patel M, Eskander SS, Gudsoorkar P, Jhaveri KD, Perazella MA, Hanna PE. Nephrotoxicity of Conventional Chemotherapeutics: Part II - Non-Platinum Agents and Miscellaneous Nephrotoxic Drugs. Nephrol Dial Transplant, 2025. e-Pub 2025. PMID: 41105138.
- Ward, K, Page, VD, Song, J, Amaram-Davila, JS, Mamlouk, O, Abudayyeh, A. Correcting hyponatraemia is associated with improved survival in hyponatraemic metastatic cancer patients. Clinical Kidney Journal 18(3), 2025. e-Pub 2025. PMID: 40052166.
- Boshkos MC, Nieves-Jimenez HR, Thakkar PH, Cintron-Garcia JJ, Mamlouk O. Nilotinib-Induced Unilateral Renal Artery Stenosis: A Complication Prompting Treatment-Free Remission in Chronic Myeloid Leukemia. Case Rep Oncol Med 2025:9887771, 2025. e-Pub 2025. PMID: 40959317.
- Parvathareddy, V, Selamet, U, Sen, AA, Mamlouk, O, Song, J, Page, VD, Abdelrahim, M, Diab, A, Hassan, NA, Abudayyeh, A. Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response. Cancers 15(21), 2023. e-Pub 2023. PMID: 37958355.
- Abudayyeh, A, Suo, L, Lin, Y, Mamlouk, O, Hassan, NA, Tchakarov, A. Pathologic Predictors of Response to Treatment of Immune Checkpoint Inhibitor–Induced Kidney Injury. Cancers 14(21), 2022. e-Pub 2022. PMID: 36358686.
- Gupta, S, Strohbehn, IA, Wang, Q, Hanna, PE, Seethapathy, R, Prosek, JM, Herrmann, SM, Abudayyeh, A, Malik, AB, Loew, S, Carlos, CA, Chang, WT, Beckerman, P, Mithani, Z, Shah, CV, Renaghan, AM, de Seigneux, S, Campedel, L, Kitchlu, A, Shin, DS, Coppock, G, Lumlertgul, N, Garcia, P, Ortiz-Melo, DI, Rashidi, A, Sprangers, B, Aggarwal, V, Benesova, K, Jhaveri, KD, Cortazar, FB, Weins, A, Zuo, Y, Mooradian, MJ, Reynolds, KL, Leaf, DE, Sise, ME, Salem, JE, Bagnis, CI, Singh, H, Motwani, SS, Murakami, N, Tio, MC, Mothi, SS, Selamet, U, Schmidt-Ott, KM, Chang, W, Wanchoo, R, Khanin, Y, Mamlouk, O, Lin, JS. Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer. Kidney International 102(4):930-935, 2022. e-Pub 2022. PMID: 35964800.
- Weng J, Ajani JA, Murphy MB, Badgwell BD, Tchakarov AS, Mamlouk O, Das AP. Immunotherapy Recall: Radiation Induced Reactivation of Immune Checkpoint Inhibitor Nephritis. JCO Precision Oncology, 2022. e-Pub 2022. PMID: 35952321.
- Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, Ostermann M, Herrmann SM, Abudayyeh A, Anand S, Glezerman I, Motwani SS, Murakami N, Wanchoo R, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, Seigneux S, Campedel L, Kitchlu A, Shin DS, Rangarajan S, Deshpande P, Coppock G, Eijgelsheim M, Seethapathy H, Lee MD, Strohbehn IA, Owen DH, Husain M, Garcia-Carro C, Bermejo S, Lumlertgul N, Seylanova N, Flanders L, Isik B, Mamlouk O, Lin JS, Garcia P, Kaghazchi A, Khanin Y, Kansal SK, Wauters E, Chandra S, Schmidt-Ott KM, Hsu RK, Tio MC, Sarvode Mothi S, Singh H, Schrag D, Jhaveri KD, Reynolds KL, Cortazar FB, Leaf DE, Investigators IC. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer 9(10), 2021. e-Pub 2021. PMID: 34625513.
- Abdelrahim M, Mamlouk O, Lin H, Lin J, Page V, Abdel-Wahab N, Swan J, Selamet U, Yee C, Diab A, Suki W, Abudayyeh A. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis. Oncoimmunology 10(1):1927313, 2021. e-Pub 2021. PMID: 34104543.
- Mamlouk O, Nair R, Iyer SP, Edwards A, Neelapu SS, Steiner RE, Adkins SA, Hawkins M, Saini N, Devashish K, Strati P, Mandayam S, Ahmed S. Safety of CAR T-cell therapy in kidney transplant recipients. Blood 137(18):2558-2562, 2021. e-Pub 2021. PMID: 33512386.
- Strasma A, Coke H, Mamlouk O, Tchakarov A, Mandayam S. Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor. Kidney Med 3(2):294-298, 2021. e-Pub 2021. PMID: 33851126.
- Lin JS, Mamlouk O, Selamet U, Tchakarov A, Glass WF, Sheth RA, Layman RM, Dadu R, Abdelwahab N, Abdelrahim M, Diab A, Yee C, Abudayyeh A. Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology 10(1):1877415, 2021. e-Pub 2021. PMID: 33643693.
- Abudayyeh, A, Lin, Y, Mamlouk, O, Abdelrahim, M, Saliba, RM, Rondon, G, Martinez, C, Delgado, R, Page, VD, Rajasekaran, A, Sanders, PW, Qazilbash, MH. Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma. Leukemia and Lymphoma 61(13):3101-3111, 2020. e-Pub 2020. PMID: 32723196.
- Lin, JS, Wang, DY, Mamlouk, O, Glass, W, Abdelrahim, M, Yee, C, Abudayyeh, A. Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab. Journal for immunotherapy of cancer 8(2), 2020. e-Pub 2020. PMID: 33020246.
- Mamlouk, O, Lin, JS, Abdelrahim, M, Tchakarov, A, Glass, W, Selamet, U, Buni, M, Hassan, NA, Abudayyeh, A. Checkpoint inhibitor-related renal vasculitis and use of rituximab. Journal for immunotherapy of cancer 8(2), 2020. e-Pub 2020. PMID: 32718987.
- Cortazar, FB, Kibbelaar, ZA, Glezerman, I, Abudayyeh, A, Mamlouk, O, Motwani, SS, Murakami, N, Herrmann, SM, Manohar, S, Shirali, A, Kitchlu, A, Shirazian, S, Assal, A, Vijayan, A, Renaghan, AM, Ortiz-Melo, DI, Rangarajan, S, Malik, AB, Hogan, JJ, Dinh, AR, Shin, DS, Marrone, KA, Mithani, Z, Johnson, DB, Hosseini, A, Uprety, D, Sharma, S, Gupta, S, Reynolds, KL, Sise, ME, Leaf, DE. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI. Journal of the American Society of Nephrology 31(2):435-446, 2020. e-Pub 2020. PMID: 31896554.
- Cortazar, F, Kibbelaar, Z, Glezerman, I, Abudayyeh, A, Mamlouk, O, al E. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. JASN 31(2):435-446, 2020. e-Pub 2020.
- Mamlouk, O, Workeneh, B. A case of relapsing immunoglobulin A nephropathy secondary to immunotherapy. Journal of Onco-Nephrology:1-5, 2020. e-Pub 2020.
- Mamlouk, O, Selamet, U, Machado, S, Abdelrahim, M, Glass, W, Tchakarov, A, Gaber, L, Lahoti, A, Workeneh, BT, Chen, S, Lin, JS, Hassan, NA, Tayar, JH, Lu, H, Suarez-Almazor, M, Tannir, NM, Yee, C, Diab, A, Abudayyeh, A. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis. Journal for immunotherapy of cancer 7(1), 2019. e-Pub 2019. PMID: 30612580.
- Mamlouk, O, Hninn, W, Mandayam, S, Workeneh, B. Acute kidney injury associated with high dose methotrexate. Journal of Onco-Nephrology 4 (1-2):64-65, 2019. e-Pub 2019.
- Mamlouk, O, Lin, J S, Zhang, H, Glass, W F, Amaria, R N, Lahoti, A, Workeneh, B T. Tubulointerstitial and intraglomerular metastasis with subsequent development of tumor lysis syndrome in a patient with advanced metastatic melanoma. Journal of Onco-Nephrology 2 1:24-30, 2018. e-Pub 2018.
- Zhu, Z, Liu, W, Mamlouk, O, O’Donnell, JE, Sen, D, Avezbakiyev, B. Primary pulmonary diffuse large b cell non-hodgkin’s lymphoma. American Journal of Case Reports 18:286-290, 2017. e-Pub 2017. PMID: 28321110.
- Mamlouk, O, Balagurumoorthy, P, Wang, K, Adelstein, SJ, Kassis, AI. Bystander effect in tumor cells produced by Iodine-125 labeled human lymphocytes. International journal of radiation biology 88(12):1019-1027, 2012. e-Pub 2012. PMID: 22712702.
- Riss O, Mamlouk O, Troufleau P, Depardieu C, Stines J. Une tumeur fibreuse solitaire de la cuisse exploree par TDM et IRM. J Radiol 81(11):1643-6, 2000. e-Pub 2000. PMID: 11104981.
Invited Articles
- Mamlouk O, Farhad Danesh. Immune Checkpoint Inhibitor-Associated Nephrotoxicity. Nephron 148(1):11-15, 2023. e-Pub 2023. PMID: 37257429.
- Mamlouk, O, Bonilla, M, Motwani &, S. A Path to Training in Onconephrology. Kidney News 14(6):28, 2022. e-Pub 2022.
- Adhikari S, Mamlouk O, Rondon-Berrios H, Workeneh BT. Hypophosphatemia in cancer patients. Clin Kidney J 14(11):2304-2315, 2021. e-Pub 2021. PMID: 34754427.
- Mamlouk, O, Abudayyeh, A. Cancer immunotherapy and its renal effects. Journal of Onco-Nephrology 3:151-159, 2019. e-Pub 2019.
Review Articles
- Kelly, A, Sharma, S, Mamlouk, O, Hassanein, M, Chowdhury, RB, Gupta, S, Troung, H, Bonilla, M, Kalra, K, Wanchoo, R, Pariswala, T, Turcotte, A, Zaveri, I, Dernell, C, Ibrahim, M, Patel, M, Eskander, SS, Gudsoorkar, P, Jhaveri, KD, Perazella, MA, Hanna, PE. Nephrotoxicity of conventional chemotherapeutics. Nephrology Dialysis Transplantation 41(6):1011-1022, 2026. e-Pub 2026. PMID: 41247096.
- Alasadi, Y, Garcia, JC, Arani, N, Page, VD, Geng, Y, Andersen, C, Tchakarov, A, Kitchlu, A, Mamlouk, O, Abudayyeh, A. Rituximab for the treatment of immune checkpoint inhibitor–induced glomerulonephritis. Clinical Kidney Journal 19(1), 2026. e-Pub 2026. PMID: 41788614.
- Turcotte, A, Achi, S, Mamlouk, O, Mandayam, S. Electrolytes disturbances in cancer patients. Current opinion in nephrology and hypertension 31(5):425-434, 2022. e-Pub 2022. PMID: 35894276.
Abstracts
- Mamlouk O, Turin A, D`Achiardi D, Simbaqueba C, Dickson K, Franco-Vega M, Halm J, Mandayam S, team AD. Clinical characteristics and outcomes of cancer patients with chronic kidney disease and coronavirus disease 2019. Journal of Clinical Oncology, 2021. e-Pub 2021.
- Simbaqueba C, Mamlouk O, Dickson K, Franco-Vega M, Halm J, Mandayam S Turin A, D`Achiardi D, Franco-Vega M, Team AD. Clinical characteristics and outcomes of cancer patients without chronic kidney disease and coronavirus disease 2019. Journal of Clinical Oncology, 2021. e-Pub 2021.
- Mamlouk, O Ahmed O, A, Coke H, Mandayam A, S. Narsoplimab, Another Tool in the Management of TMA in Stem Cell Transplant Recipients. JASN Abstract supp, 2020. e-Pub 2020.
- Mamlouk, O, Lin, J, Abdelrahim, M, Tchakarov, A, Glass, FW, Selamet, U, Buni, M, Abdel-Wahab, N, Abudayyeh A. Checkpoint inhibitors related renal vasculitis and use of rituximab. Journal of Clinical Oncology, 2020. e-Pub 2020.
- Mamlouk, O, Workeneh, B, Mandayam A, S. Eosinophilic Granulomatosis with Polyangiitis in Patient Treated with Chemokine Receptor Type 4 Antibody. KI Reports, 2020. e-Pub 2020.
- Van Norman M, Mamlouk, O, and Workeneh B. Atypical Hemolytic Uremic Syndrome Attributed to Complement Dysregulation in Setting of Metastatic Prostate Cancer Patient. JASN Abstract supp, 2020. e-Pub 2020.
- Mamlouk, O, Workeneh, B, Mandayam A, S Checkpoint inhibitors: The Double-Edged Sword in Kidney Transplant Patients S. Checkpoint inhibitors: The Double-Edged Sword in Kidney Transplant Patients. JASN Abstract supp, 2019. e-Pub 2019.
- Mandayam, S, Mamlouk, O, Airy, M, Rodriguez, M, Perez, J. Effect of Ferric Citrate on Erythropoiesis-Stimulating Agent (ESA) Use in ESRD Patients with Elevated Ferritin. JASN Abstract supp, 2019. e-Pub 2019.
- Mamlouk, O, Turfah, A, Page, P, Zarinkumar, N, Workeneh, B, Mandayam A, S. Rasbucricase resistant tumor lysis syndrome: analysis of patient characteristics. AJKD 73(5):699, 2019. e-Pub 2019.
- Mamlouk, O, Khairalla, H, Glass W, and Khattak A. Double trouble or a separate entity; AKI secondary to ANCA vasculitis with IgG4 nephropathy. JASN Abstract supp, 2018. e-Pub 2018.
- Mamlouk, O, Khairalla, H, Glass W, and Khattak A. Double trouble or a separate entity; AKI secondary to ANCA vasculitis with IgG4 nephropathy. JASN Abstract supp, 2018. e-Pub 2018.
- Humberto Jiménez, Mamlouk O. Mystery of Declining Renal Function: Renal Artery Stenosis Induced by Nilotinib in a Chronic Myeloid Leukemia Patient. ACP-Texas Chapter.
- Naszrin Arani, Ratanasrimetha P, Lin H, Mamlouk O, Tchakarov A, Rondon G, Shpall EJ, Abudayyeh Ala. Transplant-Associated Renal Thrombotic Microangiopathy after Allogeneic SCT. ASTCT.
- Cesar Simbaqueba Clavijo, Mamlouk O, Dickson K, Franco-Vega M, Knafl M, Song H, Sreedhar Mandayam. CHRONIC KIDNEY DISEASE IMPACT ON CORONAVIRUS (COVID-19) INFECTION SEVERITY AND OUTCOMES IN CANCER PATIENTS. International Society of Nephrology.
Book Chapters
- Mamlouk O, Lin JS, Abudayyeh A. Immune checkpoint inhibitor-induced kidney toxicity. In: Managing Immunotherapy Related Organ Toxicities: A Practical Guide, 197-214, 2022.
- Mamlouk, O, Lin, JS, Abudayyeh, A. Nephrology (Kidney), 197-214, 2022.
- Mamlouk O, Bejjanki H, Workeneh B. Acute Kidney Injury in Malignancy. In: Issues in Kidney Disease – Acute Kidney Injury, 2021.
- Bejjanki H, Mamlouk O, Workeneh B. End-Stage Kidney Disease and Malignancy. In: Issues in Kidney Disease – Dialysis, 2021.
Letters to the Editor
- Mamlouk O, Paolo Strati, Lei Feng, Ryan Sun, Amy Ayers, Raphael E. Steiner, Ranjit Nair, Christopher Flowers, Jeremy L. Ramdial, Neeraj Saini, Samer A. Srour, Richard E. Champlin, Partow Kebriaei, Loretta J. Nastoupil, Maria A. Rodriguez, Elizabeth J. Shpall, Yago Nieto, Jason Westin, Sattva S. Neelapu, Sreedhar Mandayam, Sairah Ahmed. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. bjhaem 204: e11-e16, 2023.
- Kala, J, Mamlouk, O, Jhaveri, KD. Selinexor-associated hyponatremia. Kidney International 98: 789-791, 2020.
Web Publications
- Biruh W, Mamlouk O. Acute Kidney Injury (AKI), 2022.
Patient Reviews
CV information above last modified September 10, 2026